• MedSci disclosed 2025-26 subscriptions of CR Notes totaling US$ 63.3 million, later cut to US$ 48.3 million after a US$ 15 million redemption.
• Three subscriptions used Global Offering proceeds, described as a temporary deviation due to an internal misclassification of the product’s nature.
• Outstanding CR Notes are expected to be redeemed on Nov. 4, 2026; gains or losses will be finalized at redemption.
• MedSci set new compliance controls for treasury investments, including mandatory size-test checks, funding-source certification, and external counsel sign-off triggers.
• A principal-protected structured deposit of RMB 50 million matured June 16, 2026, generating RMB 487,500 in realized gain at a 1.95% annualized rate.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MedSci Healthcare Holdings Ltd. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260804-12270147), on August 04, 2026, and is solely responsible for the information contained therein.